Company intelligence / Profile preview

SmartHealth Holdings

United States

Ownership: Private
Development stage: Other

Overview

The SmartVascular Dx platform is clinically validated for sensitive/specific vascular inflammation detection and is commercially available. Their oncology and pathology technologies are advancing early detection and diagnostic accuracy

Therapeutic areas: OncologyCardiovascularOther
Modalities: DeviceDiagnostic platform
Industry: Pathology

Partnerships

None specified; one director is a founder of Hangzhou Huili Medical, which partners with Roche, Johnson & Johnson, Abbott Diagnostics, Thermo Fisher—these may be indirect partnerships

Beyond the preview

Go deeper on SmartHealth Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SmartHealth Holdings.

Explore the full profile